XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net sales:        
Net sales $ 2,925 $ 2,820 $ 8,713 $ 8,776
Segment Adjusted Operating EBITDA:        
Adjusted Operating EBITDA 568 506 1,734 1,519
Depreciation & Amortization 248 292 772 855
Interest expense (74) (90) (236) (291)
Other (expense) income, net (28) 9 (44) 17
Restructuring and other charges, net (1) (2) (6) (61)
Goodwill, impairment loss 0 0 (64) 0
(Gains) Losses on business disposals 20 10 (348) 29
Loss on held for sale classification (32) 0 (314) 0
Acquisition, divestiture, and integration related costs 55 42 172 118
Strategic initiative costs (6) (6) (22) (28)
Regulatory costs (10) (13) (64) (32)
Other gains (losses) 1 (1) 5 1
Income before taxes 95 59 393 123
Integration-related costs   (12) (5) (42)
Transaction related costs   (1)   (6)
Business divestiture costs 55 29 167 70
Nourish        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 (1) (3) (33)
Health & Biosciences        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 (1) (1) (12)
Scent        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net 0 0 (1) (14)
Pharma Solutions        
Segment Adjusted Operating EBITDA:        
Restructuring and other charges, net (1) 0 (1) (2)
Goodwill, impairment loss     (64)  
Operating Segments | Nourish        
Net sales:        
Net sales 1,486 1,449 4,460 4,666
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 206 178 654 567
Operating Segments | Health & Biosciences        
Net sales:        
Net sales 570 518 1,659 1,553
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 173 150 497 426
Operating Segments | Scent        
Net sales:        
Net sales 613 615 1,861 1,815
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA 127 131 421 353
Operating Segments | Pharma Solutions        
Net sales:        
Net sales 256 238 733 742
Segment Adjusted Operating EBITDA:        
Segment Adjusted Operating EBITDA $ 62 $ 47 $ 162 $ 173